MDNAF Medicenna Therapeutics Corp

$MDNAF SITC 2026: this is the first time MDNA & its authors claimed efficacy. Across ASCO, ESMO, AACR, and SITC 2024–2025, MDNA used softer, neutral phrasing — never once an efficacy claim. The tone changed with SITC 2026, where MDNA11 used a headline level efficacy phrase, not one buried in the text. That’s a confidence signal. You don’t get to say “demonstrates clinical activity” unless reviewers see real, reproducible anti-tumor effect. authors pick the abstract title-not more than 200 characters, SITC reviews it for compliance — character limit, accuracy, and no exaggerated claims. SITC only allows efficacy type wording when reviewers agree the data truly support it. Out of all abstracts released so far, only MDNA11 claims in- human efficacy (“clinical activity”) in the title- This is extremely rare. In 2025 none of the abstracts made such a claim. SITC is conservative with clinical claims. Everyone who’s actually seen the data seems to agree on one thing — MDNA11 is crushing it.

$MDNAF A clinical program generally needs 3 layers of validation before it can credibly “break out”: (1) Biological / Mechanistic Validation (2) Safety & Tolerability Validation (3) Clinical Efficacy Validation — the true breakout trigger The 1st 2 almost never move a stock in a durable way. You get a spike, then a sell off, we've seen this 3x with MDNA because mechanism and safety alone are not enough to bring in the big players —who anchor a valuation. They wait for the only thing that matters MDNA11 already checks the 1st 2 boxes. But lacks the most important validation: clinical proof of efficacy. That’s why the approved SITC title — explicitly emphasizing clinical efficacy — is so telling. It signals that Mdna's finally ready to address the 1 missing pillar. If SITC delivers confirmed, durable tumor shrinkage at therapeutic dose, MDNA11 transitions from “scientifically interesting” to “clinically undeniable.” That's the moment the MDNA becomes investable for serious capital & pharma

$MDNAF Medicenna quietly added a Chief Business Advisor, John Mayfield, PhD — no press release, but he’s on their website and his LinkedIn shows he joined a 3-4 months ago. His LindkIn suggests he contributed to securing a deal with Merck at his previous. A CBA is a strategic hire used when a biotech is entering a critical phase where it needs to turn clinical progress into business outcome. It may also signal Medicenna is opening the door to options beyond Merck & possibly a bidding war with CBA managing inbound interests.

$MDNAF Abstract Title posted…”Top 150” look cool!!! Abstract #517 Presents Friday, Nov. 6 Top 150 🎗 MDNA11 Demonstrates Clinical Activity as Monotherapy and in Combination with Pembrolizumab in Biomarker-Enriched Gastrointestinal Malignancies, Including ICI-Refractory Disease Presenting Author Andre Mansinho – START Lisbon, ULSSM – Hospital de Santa Maria,Gulbenkian Institute for Molecular Medicine,Faculty of Medicine, University of Lisbon Authors Andre Mansinho, Victoria Atkinson, Philippe Bedard, Pablo Gajate, Jacqueline Brown, Luis Cabezón-Gutiérrez, Austin Duffy, Victor Moreno, Kim Margolin, Przemyslaw Twardowski, Irene Moreno, Hong Shue, Ira Winer, Michael Chisamore, Marc Oliva, Amy Prawira, Fahar Merchant, Rosemina Merchant, William Gwynne, Minh To, Nageatte Ibrahim, Arash Yavari, Melissa Coello, Hussein Tawbi, Sara Coelho, Igor Medic, Tatiana Hernandez-Guerrero, Paolo Ascierto

$MDNAF A few months ago he posted that Medicenna was at ASCO and BIO and invited people to meet to hear about MDNA11, MDNA113 and bizaxofusp. And on September 9–10—literally this week—he participated in Boston’s Oncology & Immunology Innovation Partnering & Licensing Summit, whose stated purpose is to put pharma BD/search-and-evaluation people together with biotechs for licensing and co-development discussions. Attending companies included Merck, Lilly, J&J, Takeda, Novartis and other

$MDNAF Resolution passed… If they do a split before the next data dump it’s over boys and girls.